TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of $5.11 billion. The enterprise value is $5.22 billion.
Important Dates
The next estimated earnings date is Monday, May 4, 2026, before market open.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TG Therapeutics has 159.69 million shares outstanding. The number of shares has increased by 0.67% in one year.
| Current Share Class | 147.68M |
| Shares Outstanding | 159.69M |
| Shares Change (YoY) | +0.67% |
| Shares Change (QoQ) | -1.01% |
| Owned by Insiders (%) | 4.52% |
| Owned by Institutions (%) | 73.16% |
| Float | 140.95M |
Valuation Ratios
The trailing PE ratio is 11.55 and the forward PE ratio is 24.04. TG Therapeutics's PEG ratio is 0.13.
| PE Ratio | 11.55 |
| Forward PE | 24.04 |
| PS Ratio | 8.29 |
| Forward PS | 5.55 |
| PB Ratio | 7.07 |
| P/TBV Ratio | 7.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.13 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 11.67 |
| EV / Sales | 8.47 |
| EV / EBITDA | 42.30 |
| EV / EBIT | 42.32 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.10, with a Debt / Equity ratio of 0.39.
| Current Ratio | 4.10 |
| Quick Ratio | 2.91 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 2.03 |
| Debt / FCF | n/a |
| Interest Coverage | 4.61 |
Financial Efficiency
Return on equity (ROE) is 102.75% and return on invested capital (ROIC) is 16.55%.
| Return on Equity (ROE) | 102.75% |
| Return on Assets (ROA) | 9.39% |
| Return on Invested Capital (ROIC) | 16.55% |
| Return on Capital Employed (ROCE) | 13.56% |
| Weighted Average Cost of Capital (WACC) | 14.18% |
| Revenue Per Employee | $1.54M |
| Profits Per Employee | $1.12M |
| Employee Count | 399 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 0.85 |
Taxes
| Income Tax | -339.79M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.28% in the last 52 weeks. The beta is 1.86, so TG Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.86 |
| 52-Week Price Change | -25.28% |
| 50-Day Moving Average | 29.76 |
| 200-Day Moving Average | 32.17 |
| Relative Strength Index (RSI) | 61.39 |
| Average Volume (20 Days) | 2,205,439 |
Short Selling Information
The latest short interest is 28.15 million, so 17.63% of the outstanding shares have been sold short.
| Short Interest | 28.15M |
| Short Previous Month | 27.52M |
| Short % of Shares Out | 17.63% |
| Short % of Float | 19.97% |
| Short Ratio (days to cover) | 17.74 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of $616.29 million and earned $447.18 million in profits. Earnings per share was $2.77.
| Revenue | 616.29M |
| Gross Profit | 515.57M |
| Operating Income | 123.32M |
| Pretax Income | 107.39M |
| Net Income | 447.18M |
| EBITDA | 123.38M |
| EBIT | 123.32M |
| Earnings Per Share (EPS) | $2.77 |
Full Income StatementBalance Sheet
The company has $141.97 million in cash and $254.40 million in debt, with a net cash position of -$112.43 million or -$0.70 per share.
| Cash & Cash Equivalents | 141.97M |
| Total Debt | 254.40M |
| Net Cash | -112.43M |
| Net Cash Per Share | -$0.70 |
| Equity (Book Value) | 648.02M |
| Book Value Per Share | 4.52 |
| Working Capital | 477.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$24.77 million and capital expenditures -$214,000, giving a free cash flow of -$24.99 million.
| Operating Cash Flow | -24.77M |
| Capital Expenditures | -214,000 |
| Depreciation & Amortization | 59,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -24.99M |
| FCF Per Share | -$0.16 |
Full Cash Flow StatementMargins
Gross margin is 83.66%, with operating and profit margins of 20.01% and 72.56%.
| Gross Margin | 83.66% |
| Operating Margin | 20.01% |
| Pretax Margin | 17.43% |
| Profit Margin | 72.56% |
| EBITDA Margin | 20.02% |
| EBIT Margin | 20.01% |
| FCF Margin | n/a |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.67% |
| Shareholder Yield | -0.67% |
| Earnings Yield | 8.76% |
| FCF Yield | -0.49% |
Analyst Forecast
The average price target for TG Therapeutics is $49.80, which is 55.72% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $49.80 |
| Price Target Difference | 55.72% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 26.27% |
| EPS Growth Forecast (5Y) | 8.61% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on April 30, 2012. It was a reverse split with a ratio of 1:56.25.
| Last Split Date | Apr 30, 2012 |
| Split Type | Reverse |
| Split Ratio | 1:56.25 |
Scores
TG Therapeutics has an Altman Z-Score of 7.29 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.29 |
| Piotroski F-Score | 3 |
